Tag Archives: MDGL

H.C. Wainwright Thinks Madrigal Pharmaceuticals Inc’s Stock is Going to Recover

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL – Research Report), with a price target of $313. The company’s shares closed yesterday at $114.63, close to its 52-week low

Madrigal Pharmaceuticals Inc (MDGL) Received its Third Buy in a Row

After Cowen & Co. and H.C. Wainwright gave Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals Inc today and

The CEO of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) is Buying Shares

Yesterday, the CEO of Madrigal Pharmaceuticals Inc (MDGL – Research Report), Paul A. Friedman, bought shares of MDGL for $471.5K. This recent transaction increases Paul A. Friedman’s holding in the company by 2.55% to a total of $18.27 million. In

Madrigal Pharmaceuticals Inc (MDGL) Receives a Rating Update from a Top Analyst

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL – Research Report) today. The company’s shares opened today at $210.34. According to TipRanks.com, Baral is a top 100 analyst with an average return of

Oppenheimer Remains a Buy on Madrigal Pharmaceuticals Inc (MDGL)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL – Research Report), with a price target of $300. The company’s shares closed yesterday at $208.38. Olson commented: “MDGL released 3Q18 financial

Madrigal Pharmaceuticals Inc (MDGL) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) today and set a price target of $300. The company’s shares opened today at $203.20. Olson said: “Viking Therapeutics announced positive top line data from a